Depression and Mood Disorders
The Mental Health Center Sofia EOOD conducts extensive studies on Major Depressive Disorder and related mood conditions, aiming to improve treatment options for patients who have not responded adequately to standard antidepressants.
- Adjunctive novel compounds
- Anhedonia‑targeted interventions
- Anxious distress sub‑analyses
- Long‑term safety extensions
Across 12 trials, eight investigators evaluate new therapeutic approaches, enhancing care for individuals with depression in Sofia, Bulgaria.
Schizophrenia and Psychotic Disorders
Research at the site focuses on Schizophrenia, testing adjunctive agents to reduce persistent symptoms and assess tolerability over extended periods.
- Positive and Negative Syndrome Scale (PANSS) outcomes
- Adjunctive antipsychotic strategies
- Oral long‑acting formulations
- Safety monitoring in chronic use
The department’s expertise in severe mental illness supports innovative trials that may reshape standard care for schizophrenia patients.
Neuropsychiatric Symptoms in Alzheimer’s Disease
A subset of studies addresses agitation linked to Alzheimer’s disease, evaluating rapid‑acting combinations to calm patients while maintaining safety.
- CMAI‑IPA agitation scoring
- Combination therapy with KarXT + KarX‑EC
- Open‑label extension for durability
- Safety profiling in elderly cohorts
These investigations broaden the Center’s portfolio beyond primary psychiatric disorders, reflecting a commitment to comprehensive behavioral health research.
